Bloom Burton & Co. Announces the 2022 Bloom Burton Award
Annual Award Recognizes the Most Significant Contributor to Canada's Innovative Healthcare Industry
Toronto, Ontario--(Newsfile Corp. - January 25, 2022) - Bloom Burton & Co. ("Bloom Burton") is excited to announce the launch of the 2022 Bloom Burton Award and the Bloom Burton Award Gala event to be held at the Four Seasons Hotel in Toronto, Ontario, Canada on Thursday, September 29, 2022.
Bestowed annually, the Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, investor or policy maker who made the greatest contribution to Canada's innovative healthcare industry in the previous year. Nominees will be accepted from any of the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, services or digital health sectors, and equal consideration will be given to contributions across any stage of development - from discovery to approved and on market products and services. The Bloom Burton Award recognizes the individual for their specific, significant contribution from the previous year.
The Bloom Burton Award winner will be chosen by an esteemed panel of judges, all of whom are respected international leaders in healthcare investment, entrepreneurship and journalism:
- Michael Altman, Managing Director, Perceptive Advisors
- Christopher Arendt, Head of Oncology Therapeutic Area Unit, Takeda
- Karen Bernstein, Co-Founder and Chairman, BioCentury
- Carl Gordon, Managing Partner, OrbiMed Advisors
- Dennis Purcell, Founder and Senior Advisor, Aisling Capital
- Melinda Richter, Global Head, Johnson & Johnson Innovation - JLABS
- Camille Samuels, Partner, Venrock
Nominations may be submitted by the public at large on or before April 4, 2022. A narrowed list of three finalists will be announced at the Bloom Burton & Co. Healthcare Investor Conference, May 2-3, 2022. All three finalists, along with their family and friends, will be invited to and celebrated at the Bloom Burton Award Gala on September 29, 2022. Each of the three finalists will receive a $25,000 cash prize, and a single winner will receive the 2022 Bloom Burton Award. A limited number of tickets are available for industry sponsors and individuals; please visit www.bloomburton.com for more information.
Jolyon Burton, Co-Founder and President of Bloom Burton, commented, "The 2022 Bloom Burton Award will focus a bright light on the important work of our three as yet to be nominated finalists. We can't wait to learn about whom the public will put forward to the judges to showcase their dramatic and positive impact in healthcare last year."
Kindly send single page nomination letters to:
Tel: (416) 640-7575
For table sponsorship and other inquiries:
Chairman & CEO
Tel: (416) 640-7580
About Bloom Burton & Co.
Bloom Burton & Co. is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, industry and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, direct investing and company creation and incubation services. Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is also a member of the Canadian Investor Protection Fund (CIPF). Please visit www.bloomburton.com to learn more.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/111476